In adult CML data, the 3-month BCR::ABL1 ≤ 10% threshold as a critical prognostic landmark associated with superior survival and response outcomes [11,35]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.